Chardan lowered the firm’s price target on Metagenomi (MGX) to $11 from $12. The firm updated its model for Q2 financials and takes a slightly ...

Metagenomi, Inc. (NASDAQ:MGX) just released its latest quarterly results and things are looking bullish. The results overall were credible, with revenues of US$8.5m beating expectations by 10%.

Reports Q2 revenue $8.51M, consensus $7.72M. The company ended the quarter with $205.M in cash, cash equivalents, and marketable securities, which ...

Metagenomi Inc. (MGX) on Tuesday reported a loss of $19.9 million in its second quarter.

In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results - Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with ...

Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene ...

Metagenomi, Inc., with a market cap of US$52.71 million, is navigating the volatile terrain of penny stocks with its innovative gene-editing technologies. Despite being pre-revenue and ...

Metagenomi, Inc.: A Buy Rating for Pioneering Gene Editing Advancements TipRanks Mar. 5, 2024, 04:45 AM ...

On February 13, 2024, Metagenomi announced the closing of its initial public offering of 6,250,000 shares of its common stock at a price to the public of $15.00 per share. The aggregate gross ...

expand Brian Thomas, CEO of Metagenomi Inc. Todd Johnson | San Francisco Business Times By Kevin Truong – Assistant Managing Editor, San Francisco Business Times May 6, 2021 ...

Metagenomi, a start-up quietly founded by University of California, Berkeley, scientists in 2018, has raised $65 million in series A financing. The name refers to the growing field of metagenomics ...